Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

259
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
259
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

204
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
204
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

795
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
795
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

998
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
998
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

663
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
663
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

2.0K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bridging the gap in delirium management: a European comparison of geriatric practices.

European geriatric medicine·2026
Same author

GLO1 cg26053840 Methylation Associates with Kidney Injury and Inflammatory Markers in Hospitalized Older Adults.

Life (Basel, Switzerland)·2026
Same author

Age-adjusted leukocyte telomere length predicts long-term mortality in older patients discharged from acute care hospitals.

GeroScience·2026
Same author

Response to Boland et al. "Appraisal of the references supporting STOPP/START version 3 criteria".

European geriatric medicine·2026
Same author

Geriatric medicine across countries: Specialised workforce, training and system integration challenges.

The Journal of frailty & aging·2026
Same author

Caring for older adults in the Emergency Department: a Delphi-based national consensus by the Academy of Emergency Medicine and Care and the Italian Society of Gerontology and Geriatrics.

European geriatric medicine·2026

Related Experiment Video

Updated: Sep 4, 2025

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

9.9K

Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with

Marco Zuin1, Antonio Cherubini2, Stefano Volpato3

  • 1Department of Translational Medicine, University of Ferrara, 44124, Ferrara, Italy.

Scientific Reports
|July 16, 2022
PubMed
Summary
This summary is machine-generated.

Acetyl-cholinesterase-inhibitors (AChEIs) slow cognitive decline and reduce mortality in older adults with dementia. This study found AChEIs improved Mini-Mental State Examination scores and lowered death risk in Alzheimer's and vascular dementia patients.

More Related Videos

Author Spotlight: Improving Anesthesia Protocols for Enhanced Mouse Acupuncture Research
03:26

Author Spotlight: Improving Anesthesia Protocols for Enhanced Mouse Acupuncture Research

Published on: December 8, 2023

1.3K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.6K

Related Experiment Videos

Last Updated: Sep 4, 2025

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

9.9K
Author Spotlight: Improving Anesthesia Protocols for Enhanced Mouse Acupuncture Research
03:26

Author Spotlight: Improving Anesthesia Protocols for Enhanced Mouse Acupuncture Research

Published on: December 8, 2023

1.3K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.6K

Area of Science:

  • Gerontology
  • Neuroscience
  • Pharmacology

Background:

  • Dementia, including Alzheimer's disease (LOAD), vascular dementia (VD), and Lewy body disease (LBD), significantly impacts cognitive function and survival in older adults.
  • Acetyl-cholinesterase-inhibitors (AChEIs) are a class of drugs used to manage dementia symptoms.
  • Real-world data on the long-term effects of AChEIs in diverse dementia populations are crucial for clinical decision-making.

Purpose of the Study:

  • To evaluate the impact of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline and overall survival in older patients with late-onset Alzheimer's disease (LOAD), vascular dementia (VD), or Lewy body disease (LBD).
  • To assess the real-world effectiveness of AChEIs in a large, diverse cohort of dementia patients.

Main Methods:

  • A retrospective analysis of patients diagnosed with LOAD, VD, or LBD between 2005 and 2020 from "Alzheimer's Disease Research Centers."
  • 1:1 propensity score matching created a cohort of 1,572 patients (786 treated with AChEIs, 786 not treated), with a mean follow-up of 7.9 years.
  • Cognitive decline was measured using the Mini-Mental State Examination (MMSE) score; overall survival was analyzed using multivariate Cox regression.

Main Results:

  • Patients treated with AChEIs showed a significantly slower rate of cognitive decline compared to untreated patients (average MMSE decrease of 5.4 vs. 10.8 points over 13.6 years, p < 0.001).
  • This cognitive benefit was observed in LOAD and VD, but not in LBD.
  • AChEI therapy was strongly associated with reduced all-cause mortality (Hazard Ratio: 0.59; 95% CI: 0.53-0.66) across all dementia types studied.

Conclusions:

  • Acetyl-cholinesterase-inhibitors (AChEIs) are associated with slower cognitive decline and reduced mortality in older patients with LOAD and VD.
  • The findings support the use of AChEIs as an effective treatment strategy for managing dementia symptoms and improving survival in specific patient populations.
  • Further research may be warranted to explore the differential effects of AChEIs in Lewy body disease.